125 related articles for article (PubMed ID: 22842706)
1. Mapping mutations in prostate cancer exomes.
Sunkel B; Wang Q
Asian J Androl; 2012 Nov; 14(6):801-2. PubMed ID: 22842706
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
3. Integrative Exome Sequencing Analysis in Castration-Resistant Prostate Cancer in Chinese Population.
Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
[TBL] [Abstract][Full Text] [Related]
4. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.
Sircar K; Huang H; Hu L; Liu Y; Dhillon J; Cogdell D; Aprikian A; Efstathiou E; Navone N; Troncoso P; Zhang W
PLoS One; 2012; 7(2):e31259. PubMed ID: 22363599
[TBL] [Abstract][Full Text] [Related]
5. Development and prevalence of castration-resistant prostate cancer subtypes.
Vellky JE; Ricke WA
Neoplasia; 2020 Nov; 22(11):566-575. PubMed ID: 32980775
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
7. The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing.
Guo T; Wang Y; Jia J; Mao X; Stankiewicz E; Scandura G; Burke E; Xu L; Marzec J; Davies CR; Lu JJ; Rajan P; Grey A; Tipples K; Hines J; Kudahetti S; Oliver T; Powles T; Alifrangis C; Kohli M; Shaw G; Wang W; Feng N; Shamash J; Berney D; Wang L; Lu YJ
Front Cell Dev Biol; 2020; 8():602493. PubMed ID: 33490068
[TBL] [Abstract][Full Text] [Related]
8. Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer.
Park JL; Kim SK; Kim JH; Yun SJ; Kim WJ; Kim WT; Jeong P; Kang HW; Kim SY
Genomics Inform; 2018 Sep; 16(3):71-74. PubMed ID: 30309206
[TBL] [Abstract][Full Text] [Related]
9. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
10. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
11. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy.
Shiota M; Yokomizo A; Eto M
Front Oncol; 2015; 5():304. PubMed ID: 26793621
[TBL] [Abstract][Full Text] [Related]
12. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
[TBL] [Abstract][Full Text] [Related]
13. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
Shore ND; Morgans AK; Ryan CJ
Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
[TBL] [Abstract][Full Text] [Related]
14. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
15. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
16. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
17. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Grochtdreis T; König HH; Dobruschkin A; von Amsberg G; Dams J
PLoS One; 2018; 13(12):e0208063. PubMed ID: 30517165
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
20. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
